Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

dacliximab

(duh-KLIK-sih-mab)

A drug used to keep the body from rejecting kidney transplants. It is also being studied in the treatment of some types of cancer and other conditions. Dacliximab binds to receptors for a protein called interleukin-2, which are found on some types of immune cells and cancer cells. This may help suppress the body’s immune response and it may help kill cancer cells. Dacliximab is a type of monoclonal antibody. Also called daclizumab and Zenapax.

dacliximab

Search NCI's Dictionary of Cancer Terms